Researchers receive grant for cardiovascular disease prevention in patients with CKD

Researchers from the George Institute for Global Health received a $5.5 million project grant from the National Health and Medical Research Council for research into kidney disease. With additional support provided by Bayer, the initiative aims to prevent cardiovascular disease in people who have advanced kidney disease.

According to a press release, the new international trial will evaluate whether a low dose of blood-thinning medication found to be beneficial in patients with CVD will also safely reduce the number of CV events in patients with chronic kidney disease. The release noted approximately 2,000 patients with CKD in Australia, New Zealand, Malaysia, India, China, Canada and the United Kingdom will receive a low dose of the blood thinning medication in the 5-year randomized trial, making it the first and largest trial evaluating blood-thinning medications for people with CKD. The new research will be led by the George Institute and supported by Kidney Health Australia, Bayer and researchers from around the world.

“Patients with chronic kidney disease are missing out on life-saving treatments. We hope this trial will help millions of people around the world by providing them with a medication that will prevent them from dying of a heart attack or suffering a stroke,” Sunil Badve, lead researcher and senior research fellow and associate professor of medicine at the George Institute for Global Health, UNSW Sydney, said in the release. “It’s an exciting opportunity to address this unmet need and hopefully deliver a treatment that will save lives and also save money as chronic kidney disease is a complex condition to manage.”

Reference:

www.georgeinstitute.org/media-releases/largest-ever-project-grant-to-benefit-people-with-kidney-disease

Researchers from the George Institute for Global Health received a $5.5 million project grant from the National Health and Medical Research Council for research into kidney disease. With additional support provided by Bayer, the initiative aims to prevent cardiovascular disease in people who have advanced kidney disease.

According to a press release, the new international trial will evaluate whether a low dose of blood-thinning medication found to be beneficial in patients with CVD will also safely reduce the number of CV events in patients with chronic kidney disease. The release noted approximately 2,000 patients with CKD in Australia, New Zealand, Malaysia, India, China, Canada and the United Kingdom will receive a low dose of the blood thinning medication in the 5-year randomized trial, making it the first and largest trial evaluating blood-thinning medications for people with CKD. The new research will be led by the George Institute and supported by Kidney Health Australia, Bayer and researchers from around the world.

“Patients with chronic kidney disease are missing out on life-saving treatments. We hope this trial will help millions of people around the world by providing them with a medication that will prevent them from dying of a heart attack or suffering a stroke,” Sunil Badve, lead researcher and senior research fellow and associate professor of medicine at the George Institute for Global Health, UNSW Sydney, said in the release. “It’s an exciting opportunity to address this unmet need and hopefully deliver a treatment that will save lives and also save money as chronic kidney disease is a complex condition to manage.”

Reference:

www.georgeinstitute.org/media-releases/largest-ever-project-grant-to-benefit-people-with-kidney-disease